| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RSPO2 |
| Uniprot No | Q6UXX9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-176aa |
| 氨基酸序列 | MRQYGECLHSCPSGYYGHRAPDMNRCARCRIENCDSCFSKDFCTKCKVGF YLHRGRCFDECPDGFAPLEETMECVEGCEVGHWSEWGTCSRNNRTCGFKW GLETRTRQIVKKPVKDTIPCPTIAESRRCKMTMRHCPGGKRTPKAKEKRN KKKKRKLIERAQEQHSVFLATDRANQ |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RSPO2重组蛋白的参考文献及其摘要概括：
1. **"R-spondin2 promotes mammary gland development through activation of progenitor cells"**
- **作者**: Kim KA, et al.
- **摘要**: 研究通过重组RSPO2蛋白揭示其在乳腺发育中的作用，证明其通过Wnt/β-catenin信号通路激活乳腺干细胞增殖，促进导管分支形成。
2. **"Recombinant R-spondin2 enhances intestinal regeneration by amplifying crypt stem cell activity"**
- **作者**: Zhao J, et al.
- **摘要**: 利用重组RSPO2蛋白处理肠类器官，发现其显著增强隐窝干细胞自我更新能力，加速肠道损伤修复，提示其在治疗肠道疾病中的潜在价值。
3. **"RSPO2-LGR5 axis drives aggressive behavior of colorectal cancer via Wnt signaling"**
- **作者**: Wang Y, et al.
- **摘要**: 通过重组RSPO2蛋白激活LGR5受体，揭示其在结直肠癌中通过增强Wnt通路活性促进肿瘤侵袭和化疗耐药性的分子机制。
4. **"Engineered RSPO2 fusion proteins improve bone regeneration in vivo"**
- **作者**: Smith RP, et al.
- **摘要**: 开发了一种重组RSPO2-Fc融合蛋白，证明其通过协同激活Wnt和BMP信号通路，显著促进小鼠骨缺损模型的成骨分化和组织修复。
(注：以上文献标题与作者为虚拟示例，实际文献需通过学术数据库检索获取。)
**Background of RSPO2 Recombinant Protein**
The R-spondin (RSPO) family comprises four secreted glycoproteins (RSPO1-4) that play pivotal roles in regulating Wnt/β-catenin signaling, a pathway critical for embryonic development, tissue homeostasis, and stem cell maintenance. Among them, **RSPO2** is distinguished by its unique ability to synergize with Wnt ligands to amplify β-catenin-dependent signaling. This activity is mediated through its interaction with leucine-rich repeat-containing G-protein-coupled receptors (LGR4/5/6) and the transmembrane E3 ubiquitin ligases ZNRF3/RNF43. which collectively inhibit Wnt receptor degradation, thereby enhancing pathway activation.
Structurally, RSPO2 contains two N-terminal furin-like cysteine-rich domains essential for binding to ZNRF3/RNF43. a thrombospondin domain, and a C-terminal region that interacts with heparan sulfate proteoglycans. Recombinant RSPO2 is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which are crucial for its stability and bioactivity.
Research highlights RSPO2's involvement in diverse physiological processes, including limb development, lung branching morphogenesis, and intestinal stem cell proliferation. Dysregulation of RSPO2 is linked to pathologies such as cancer (e.g., colorectal, breast), fibrosis, and congenital disorders. Its recombinant form is widely utilized in *in vitro* and *in vivo* studies to investigate Wnt pathway modulation, organoid culture optimization, and therapeutic strategies targeting tissue regeneration or oncogenesis. Quality assessments for recombinant RSPO2 often include SDS-PAGE, Western blotting, and functional assays (e.g., TOPFlash reporter) to confirm purity and activity. Overall, RSPO2 recombinant protein serves as a vital tool for dissecting Wnt signaling mechanisms and developing regenerative or anti-cancer therapies.
×
